CL2015000562A1 - Método para generar planta que contiene un polinucléotido de interés a partir de un protoplasto, que comprende aislar de una población de protoplastos, al menos uno que contiene el polinucleótido de interés y un marcador fluorescente, utilizando citometría de flujo activada por fluorescencia (facs); método de producción de semilla; y planta. - Google Patents

Método para generar planta que contiene un polinucléotido de interés a partir de un protoplasto, que comprende aislar de una población de protoplastos, al menos uno que contiene el polinucleótido de interés y un marcador fluorescente, utilizando citometría de flujo activada por fluorescencia (facs); método de producción de semilla; y planta.

Info

Publication number: CL2015000562A1
Authority: CL; Chile
Prior art keywords: polynucleotide; interest; plant; protoplasts; protoplast
Prior art date: 2012-09-07

Application number

CL2015000562A

Other languages

English (en)

Inventor

German Spangengerg

Sareena Sahab

John Mason

Original Assignee

Dow Agrosciences Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-09-07

Filing date

2015-03-06

Publication date

2015-06-12

2013-09-06 Priority claimed from US14/020,694 external-priority patent/US20140075593A1/en

2015-03-06 Application filed by Dow Agrosciences Llc filed Critical Dow Agrosciences Llc

2015-06-12 Publication of CL2015000562A1 publication Critical patent/CL2015000562A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Pulmonology (AREA)
Endocrinology (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Rheumatology (AREA)
Gynecology & Obstetrics (AREA)
Psychology (AREA)
Psychiatry (AREA)
Reproductive Health (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Gastroenterology & Hepatology (AREA)

CL2015000562A 2012-09-07 2015-03-06 Método para generar planta que contiene un polinucléotido de interés a partir de un protoplasto, que comprende aislar de una población de protoplastos, al menos uno que contiene el polinucleótido de interés y un marcador fluorescente, utilizando citometría de flujo activada por fluorescencia (facs); método de producción de semilla; y planta. CL2015000562A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261697899P	2012-09-07	2012-09-07
US14/020,694 US20140075593A1 (en)	2012-09-07	2013-09-06	Fluorescence activated cell sorting (facs) enrichment to generate plants

Publications (1)

Publication Number	Publication Date
CL2015000562A1 true CL2015000562A1 (es)	2015-06-12

Family

ID=49170904

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CL2015000255A CL2015000255A1 (es)	2012-09-07	2015-02-03	Compuestos heterociclicos derivados de alcoxipirazoles, activadores de guanilato ciclasa soluble; composicion farmaceutica que los comprende; uso para tratar enfermedad cardiovascular, enfermedad renal, hiperplasia benigna de prostata, disfuncion erectil, enfermedad de alzheimer, enfermedad de parkinson, entre otras.
CL2015000562A CL2015000562A1 (es)	2012-09-07	2015-03-06	Método para generar planta que contiene un polinucléotido de interés a partir de un protoplasto, que comprende aislar de una población de protoplastos, al menos uno que contiene el polinucleótido de interés y un marcador fluorescente, utilizando citometría de flujo activada por fluorescencia (facs); método de producción de semilla; y planta.

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
CL2015000255A CL2015000255A1 (es)	2012-09-07	2015-02-03	Compuestos heterociclicos derivados de alcoxipirazoles, activadores de guanilato ciclasa soluble; composicion farmaceutica que los comprende; uso para tratar enfermedad cardiovascular, enfermedad renal, hiperplasia benigna de prostata, disfuncion erectil, enfermedad de alzheimer, enfermedad de parkinson, entre otras.

Country Status (37)

Country	Link
US (2)	US8906904B2 (es)
EP (1)	EP2892891B1 (es)
JP (1)	JP5970134B2 (es)
KR (1)	KR101692707B1 (es)
CN (1)	CN104619695B (es)
AP (1)	AP2015008231A0 (es)
AR (1)	AR092869A1 (es)
AU (1)	AU2013312931B2 (es)
BR (1)	BR112015004529B1 (es)
CA (1)	CA2880494C (es)
CL (2)	CL2015000255A1 (es)
CY (1)	CY1122610T1 (es)
DK (1)	DK2892891T3 (es)
EA (1)	EA027244B1 (es)
EC (1)	ECSP15012804A (es)
ES (1)	ES2748798T3 (es)
GE (1)	GEP20176631B (es)
HR (1)	HRP20191755T1 (es)
HU (1)	HUE046996T2 (es)
IL (1)	IL236987A (es)
LT (1)	LT2892891T (es)
MA (1)	MA37891B1 (es)
MD (1)	MD4425C1 (es)
MX (1)	MX338887B (es)
NZ (1)	NZ703989A (es)
PE (1)	PE20151001A1 (es)
PH (1)	PH12015500457B1 (es)
PL (1)	PL2892891T3 (es)
PT (1)	PT2892891T (es)
RS (1)	RS59394B1 (es)
SG (2)	SG10201510668UA (es)
SI (1)	SI2892891T1 (es)
TN (1)	TN2015000054A1 (es)
TW (1)	TWI586661B (es)
UA (1)	UA115881C2 (es)
UY (1)	UY35012A (es)
WO (1)	WO2014039434A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2748798T3 (es) *	2012-09-07	2020-03-18	Boehringer Ingelheim Int	Alcoxi pirazoles como activadores de la guanilato ciclasa soluble
TW201625584A (zh)	2014-07-02	2016-07-16	諾華公司	茚滿及吲哚啉衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途
EP3172202B1 (en) *	2014-07-22	2020-01-29	Boehringer Ingelheim International GmbH	Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
JP2018537488A (ja)	2015-12-18	2018-12-20	ノバルティスアーゲー	インダン誘導体、ならびに可溶性グアニル酸シクラーゼ活性化剤としてのその使用
CA3039735A1 (en)	2016-10-11	2018-04-19	Bayer Pharma Aktiengesellschaft	Combination containing sgc activators and mineralocorticoid receptor antagonists
WO2019081456A1 (en)	2017-10-24	2019-05-02	Bayer Aktiengesellschaft	USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT
EP3498298A1 (en)	2017-12-15	2019-06-19	Bayer AG	The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi)
JP7314173B2 (ja)	2018-04-30	2023-07-25	バイエルアクチェンゲゼルシャフト	認知障害の治療のためのｓＧＣ活性化薬及びｓＧＣ刺激薬の使用
CA3100096A1 (en)	2018-05-15	2019-11-21	Bayer Aktiengesellschaft	1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
EP3574905A1 (en)	2018-05-30	2019-12-04	Adverio Pharma GmbH	Method of identifying a subgroup of patients suffering from dcssc which benefits from a treatment with sgc stimulators and sgc activators in a higher degree than a control group
EP3820470B1 (en)	2018-07-12	2024-09-11	Boehringer Ingelheim International GmbH	Alkoxy pyrazoles as soluble guanylate cyclase activators for use in treating portal hypertension
EP3911675A1 (en)	2019-01-17	2021-11-24	Bayer Aktiengesellschaft	Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc)
MX2022004631A (es) *	2019-10-18	2022-05-24	Fmc Corp	Metodos para la preparacion del acido 5-bromo-2-(3-cloropiridin-2- il)-2h-pirazol-3-carboxilico.
CN112079712B (zh) *	2020-09-18	2022-12-13	江苏美迪克化学品有限公司	一种对乙烯基水杨酸的制备方法
EP4259617B1 (en) *	2020-12-10	2024-10-23	Bayer Aktiengesellschaft	Substituted pyrazolo piperidine carboxylic acids
EP4011873A1 (en)	2020-12-10	2022-06-15	Bayer Aktiengesellschaft	Substituted pyrazolo piperidine carboxylic acids
GB202102895D0 (en)	2021-03-01	2021-04-14	Cambridge Entpr Ltd	Novel compounds, compositions and therapeutic uses thereof
CN118900690A (zh)	2022-03-21	2024-11-05	勃林格殷格翰国际有限公司	用于治疗门脉高压的可溶性鸟苷酸环化酶活化剂
EP4536205A1 (en)	2022-06-09	2025-04-16	Bayer Aktiengesellschaft	Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women
WO2024097316A1 (en)	2022-11-04	2024-05-10	Boehringer Ingelheim International Gmbh	Soluble guanylate cyclase activators for treating systemic sclerosis
US20240199590A1 (en) *	2022-12-09	2024-06-20	Boehringer Ingelheim International Gmbh	Solid forms of a sgc activator
WO2025036839A1 (en)	2023-08-16	2025-02-20	Boehringer Ingelheim International Gmbh	Soluble guanylate cyclase activators for treating clinically significant portal hypertension and decompensated cirrhosis

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9824310D0 (en) *	1998-11-05	1998-12-30	Univ London	Activators of soluble guanylate cyclase
WO2002026712A2 (en)	2000-09-29	2002-04-04	Millennium Pharmaceuticals, Inc.	Quaternary amines and related inhibitors of factor xa
AU2002228819A1 (en)	2000-11-22	2002-06-03	Visx Incorporated	Temperature actuated positioning device for non-linear optical elements
AR031176A1 (es)	2000-11-22	2003-09-10	Bayer Ag	Nuevos derivados de pirazolpiridina sustituidos con piridina
GB0212785D0 (en)	2002-05-31	2002-07-10	Glaxo Group Ltd	Compounds
CN1747949A (zh)	2002-12-20	2006-03-15	法马西亚公司	无环吡唑化合物
BRPI0614001A2 (pt)	2005-07-18	2011-03-01	Bayer Healthcare Ag	uso de ativadores e estimuladores de guanilato ciclase solúvel para a prevenção ou tratamento de distúrbios renais
US20080045560A1 (en)	2006-08-15	2008-02-21	Wyeth	Pyrrolidine and related derivatives useful as PR modulators
WO2008138483A1 (en) *	2007-05-12	2008-11-20	Bayer Schering Pharma Aktiengesellschaft	sGC STIMULATORS, sGC ACTIVATORS AND COMBINATIONS FOR THE TREATMENT OF UROLOGICAL DISORDERS
KR20100059952A (ko) *	2007-09-06	2010-06-04	머크 샤프 앤드 돔 코포레이션	가용성 구아닐레이트 사이클라제 활성제
CN101815514B (zh) *	2007-10-05	2012-05-09	塞诺菲-安万特德国有限公司	磺酰基取代的2-磺酰基氨基苯甲酸n-苯基酰胺在治疗疼痛中的应用
WO2009068652A1 (en)	2007-11-30	2009-06-04	Smithkline Beecham Corporation	2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines as soluble guanylate cyclase activators
PE20091258A1 (es) *	2007-12-03	2009-09-12	Smithkline Beecham Corp	Derivados de piridina como activadores de la guanilato ciclasa soluble
CN102056907B (zh) *	2008-04-04	2014-12-31	武田药品工业株式会社	杂环衍生物及其用途
WO2010015652A2 (en)	2008-08-07	2010-02-11	Smithkline Beecham Corporation	Thiazole compounds as activators of soluble guanylate cyclase
WO2010015653A1 (en) *	2008-08-07	2010-02-11	Smithkline Beecham Corporation	Pyrimidine derivatives as activators of soluble guanylate cyclase
AU2009322836B2 (en)	2008-11-25	2013-04-04	Merck Sharp & Dohme Corp.	Soluble guanylate cyclase activators
EP2387404B1 (en) *	2009-01-17	2014-06-25	Bayer Intellectual Property GmbH	Sgc stimulators and activators in combination with pde5 inhbitors for the treatment of erectile dysfunction
CN102414194A (zh)	2009-02-26	2012-04-11	默沙东公司	可溶性鸟苷酸环化酶激活剂
WO2011095553A1 (en)	2010-02-05	2011-08-11	Bayer Schering Pharma Aktiengesellschaft	Sgc stimulators or sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction
SI2531187T1 (sl) *	2010-02-05	2016-01-29	Adverio Pharma Gmbh	Stimulatorji sGC ali aktivatorji sGC sami in v kombinaciji z inhibitorji PDE5 za zdravljenje cistične fibroze
SI2576548T1 (sl) *	2010-05-26	2015-11-30	Adverio Pharma Gmbh	Uporaba sGC stimulatorjev, sGC aktivatorjev, samih in v kombinacijah s PDE5 inhibitorji za zdravljenje sistemske skleroze
EP2687210A1 (de)	2010-06-25	2014-01-22	Bayer Intellectual Property GmbH	Verwendung von Stimulatoren und Aktivatoren der löslichen Guanylatzyklase zur Behandlung von Sichelzellanämie und Konservierung von Blutersatzstoffen
EP2632551B1 (en)	2010-10-28	2016-07-06	Merck Sharp & Dohme Corp.	Soluble guanylate cyclase activators
JP5715713B2 (ja)	2011-03-10	2015-05-13	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	可溶性グアニル酸シクラーゼ活性化因子
JP5826393B2 (ja)	2011-08-12	2015-12-02	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	可溶性グアニル酸シクラーゼ活性化因子
EP2594270A3 (en)	2011-11-18	2013-07-31	BIP Patents	The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc)
ES2748798T3 (es) *	2012-09-07	2020-03-18	Boehringer Ingelheim Int	Alcoxi pirazoles como activadores de la guanilato ciclasa soluble

2013
- 2013-09-03 ES ES13762666T patent/ES2748798T3/es active Active
- 2013-09-03 DK DK13762666.9T patent/DK2892891T3/da active
- 2013-09-03 MD MDA20150019A patent/MD4425C1/ro active IP Right Grant
- 2013-09-03 PL PL13762666T patent/PL2892891T3/pl unknown
- 2013-09-03 HU HUE13762666A patent/HUE046996T2/hu unknown
- 2013-09-03 BR BR112015004529-4A patent/BR112015004529B1/pt active IP Right Grant
- 2013-09-03 GE GEAP201313783A patent/GEP20176631B/en unknown
- 2013-09-03 KR KR1020157005961A patent/KR101692707B1/ko active Active
- 2013-09-03 EA EA201500298A patent/EA027244B1/ru not_active IP Right Cessation
- 2013-09-03 AU AU2013312931A patent/AU2013312931B2/en active Active
- 2013-09-03 MA MA37891A patent/MA37891B1/fr unknown
- 2013-09-03 SG SG10201510668UA patent/SG10201510668UA/en unknown
- 2013-09-03 RS RSP20191306 patent/RS59394B1/sr unknown
- 2013-09-03 SI SI201331583T patent/SI2892891T1/sl unknown
- 2013-09-03 WO PCT/US2013/057826 patent/WO2014039434A1/en not_active Ceased
- 2013-09-03 AP AP2015008231A patent/AP2015008231A0/xx unknown
- 2013-09-03 EP EP13762666.9A patent/EP2892891B1/en active Active
- 2013-09-03 PT PT137626669T patent/PT2892891T/pt unknown
- 2013-09-03 PE PE2015000295A patent/PE20151001A1/es active IP Right Grant
- 2013-09-03 CA CA2880494A patent/CA2880494C/en active Active
- 2013-09-03 US US14/016,452 patent/US8906904B2/en not_active Ceased
- 2013-09-03 SG SG11201500861QA patent/SG11201500861QA/en unknown
- 2013-09-03 CN CN201380046266.3A patent/CN104619695B/zh active Active
- 2013-09-03 JP JP2015531142A patent/JP5970134B2/ja active Active
- 2013-09-03 NZ NZ703989A patent/NZ703989A/en unknown
- 2013-09-03 HR HRP20191755TT patent/HRP20191755T1/hr unknown
- 2013-09-03 UA UAA201503030A patent/UA115881C2/uk unknown
- 2013-09-03 LT LTEP13762666.9T patent/LT2892891T/lt unknown
- 2013-09-03 MX MX2015002807A patent/MX338887B/es active IP Right Grant
- 2013-09-06 UY UY0001035012A patent/UY35012A/es active IP Right Grant
- 2013-09-06 AR ARP130103197A patent/AR092869A1/es active IP Right Grant
- 2013-09-06 TW TW102132286A patent/TWI586661B/zh active
2015
- 2015-01-29 IL IL236987A patent/IL236987A/en active IP Right Grant
- 2015-02-03 CL CL2015000255A patent/CL2015000255A1/es unknown
- 2015-02-18 TN TNP2015000054A patent/TN2015000054A1/fr unknown
- 2015-03-03 PH PH12015500457A patent/PH12015500457B1/en unknown
- 2015-03-06 CL CL2015000562A patent/CL2015000562A1/es unknown
- 2015-04-02 EC ECIEPI201512804A patent/ECSP15012804A/es unknown
2016
- 2016-10-31 US US15/338,605 patent/USRE46886E1/en active Active
2019
- 2019-10-22 CY CY20191101099T patent/CY1122610T1/el unknown

Also Published As

Publication number	Publication date
MA37891A1 (fr)	2018-01-31
CY1122610T1 (el)	2021-03-12
PH12015500457A1 (en)	2015-04-20
EA027244B1 (ru)	2017-07-31
SG11201500861QA (en)	2015-04-29
BR112015004529A2 (pt)	2017-07-04
MA37891B1 (fr)	2018-05-31
US20140073629A1 (en)	2014-03-13
AP2015008231A0 (en)	2015-01-31
MD20150019A2 (ro)	2015-07-31
SI2892891T1 (sl)	2019-11-29
MX338887B (es)	2016-05-04
AR092869A1 (es)	2015-05-06
RS59394B1 (sr)	2019-11-29
WO2014039434A1 (en)	2014-03-13
BR112015004529A8 (pt)	2019-08-27
BR112015004529B1 (pt)	2022-06-21
EP2892891A1 (en)	2015-07-15
PT2892891T (pt)	2019-11-05
PH12015500457B1 (en)	2015-04-20
CA2880494C (en)	2021-09-21
UA115881C2 (uk)	2018-01-10
CA2880494A1 (en)	2014-03-13
CN104619695A (zh)	2015-05-13
EA201500298A1 (ru)	2015-08-31
KR20150048765A (ko)	2015-05-07
UY35012A (es)	2014-03-31
KR101692707B1 (ko)	2017-01-04
USRE46886E1 (en)	2018-06-05
CN104619695B (zh)	2018-04-10
TW201422607A (zh)	2014-06-16
MD4425B1 (ro)	2016-06-30
IL236987A (en)	2017-02-28
HUE046996T2 (hu)	2020-04-28
TWI586661B (zh)	2017-06-11
JP5970134B2 (ja)	2016-08-17
HRP20191755T1 (hr)	2019-12-27
NZ703989A (en)	2017-04-28
MD4425C1 (ro)	2017-01-31
HK1210164A1 (en)	2016-04-15
LT2892891T (lt)	2020-01-27
MX2015002807A (es)	2015-05-15
DK2892891T3 (da)	2019-10-14
ECSP15012804A (es)	2015-12-31
TN2015000054A1 (en)	2016-06-29
GEP20176631B (en)	2017-02-27
PL2892891T3 (pl)	2020-01-31
AU2013312931A1 (en)	2015-02-05
JP2015527394A (ja)	2015-09-17
US8906904B2 (en)	2014-12-09
AU2013312931B2 (en)	2017-06-22
PE20151001A1 (es)	2015-07-15
CL2015000255A1 (es)	2015-05-29
EP2892891B1 (en)	2019-07-31
SG10201510668UA (en)	2016-01-28
ES2748798T3 (es)	2020-03-18

Publication	Publication Date	Title
CL2015000562A1 (es)	2015-06-12	Método para generar planta que contiene un polinucléotido de interés a partir de un protoplasto, que comprende aislar de una población de protoplastos, al menos uno que contiene el polinucleótido de interés y un marcador fluorescente, utilizando citometría de flujo activada por fluorescencia (facs); método de producción de semilla; y planta.
MX367417B (es)	2019-08-21	Metodos de seleccion para microorganismos que imparten propiedades beneficiosas a las plantas.
HK1218310A1 (zh)	2017-02-10	鉴定细胞群体、特别是间充质干细胞群体的多色流式细胞术方法
MX2018004264A (es)	2018-11-09	Metodo para producir plantas completas a partir de protoplastos.
CL2017001873A1 (es)	2018-04-13	Métodos de purificación de cannabinoides, composiciones y kits de los mismos
GT201400265A (es)	2017-10-09	Composiciones y métodos para silenciar la expresión genética
EP3161140A4 (en)	2017-12-20	Cannabichromenic acid synthase from cannabis sativa
MX357823B (es)	2018-07-25	Receptores del antígeno quimérico que seleccionan el antígeno para la maduración de las células b.
EA201391602A1 (ru)	2014-04-30	Контролируемое высвобождение иммунодепрессантов из синтетических наноносителей
UY34095A (es)	2013-01-03	4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina
MX2019005692A (es)	2019-09-05	Procesos para producir lipidos.
ZA201501736B (en)	2016-10-26	Fluorescence activated cell sorting (facs) enrichment to generate plants
CL2014002235A1 (es)	2015-01-16	Proceso para la producción de gas de síntesis de amoníaco y una unidad inicial de una planta de amoníaco.
UY30621A1 (es)	2008-05-31	Método para la produccion de semilla de maiz hibrido y composiciones producidas a partir del mismo
GB201211142D0 (en)	2012-08-08	Microcapsules
SI2844243T1 (sl)	2020-02-28	Metoda za pripravo izolata iz rastline konoplje, ki obsega delta-9-tetrahidrokanabinol
AR088839A1 (es)	2014-07-10	Metodo para distribuir granos de polen
BR112015004074A2 (pt)	2017-07-04	método para controlar pragas, uso e semente de uma planta cultivada.
PH12014502791A1 (en)	2015-02-09	Methods for selection of introgression marker panels
AR081729A1 (es)	2012-10-17	Composicion de control de fitoenfermedades y metodo para controlar fitoenfermedades
CO6470817A2 (es)	2012-06-29	Cristales de solvato novedosos
EP3265941A4 (en)	2018-08-15	Reagent-free identification of bacteria containing resistance genes using a rapid intrinsic fluorescence method
PH12015500621B1 (en)	2015-05-11	Method for synthesising cyclohexenones and the use of same in the perfume industry
AR089733A1 (es)	2014-09-10	Transmisor de anillo de rozamiento
CO6331375A2 (es)	2011-10-20	Un proceso para la recuperacion de sulfuro metalico a partir de una solucion que contiene el ion del metal